Hochmair M.J.Morabito A.Hao D.Yang C.-T.Soo R.A.CHIH-HSIN YANGGucalp R.Halmos B.M?rten A.Cufer T.2021-04-232021-04-2320201479-6694https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097958300&doi=10.2217%2ffon-2020-0740&partnerID=40&md5=0a8b0f96808ac2cee92ae3f29932521ehttps://scholars.lib.ntu.edu.tw/handle/123456789/557701Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment ?10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Results: Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7-29.9). Median OS was 37.6 months (90% CI: 35.5-41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with EGFR mutation-positive NSCLC, especially in Del19-positive patients and Asian patients. Clinical Trial Registration: NCT03370770 (ClinicalTrials.gov. ? 2020 Maximilian J. Hochmair and other authors.afatinib; EGFR; NSCLC; osimertinib[SDGs]SDG3afatinib; epidermal growth factor receptor; osimertinib; acrylamide derivative; afatinib; aniline derivative; antineoplastic agent; EGFR protein, human; epidermal growth factor receptor; osimertinib; aged; Article; Asian; cancer chemotherapy; cancer survival; clinical practice; clinical trial; controlled study; gene mutation; human; major clinical study; non small cell lung cancer; observational study; overall survival; priority journal; survival rate; survival time; adult; genetics; lung tumor; middle aged; mortality; mutation; non small cell lung cancer; Acrylamides; Adult; Afatinib; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Middle Aged; Mutationjournal article10.2217/fon-2020-0740328545362-s2.0-85097958300